

Efavirenz + emtricitabine + tenofovir



Statut de médicament essentiel ✓

Section: 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.2. Antiretrovirals > 6.4.2.5. Fixed-dose combinations of antiretrovirals

Codes ATC: J05AR06

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Code ICD11: 1C62.Z
INN	Efavirenz + emtricitabine + tenofovir
Type de médicament	Chemical agent
Type de liste	Liste de base
Formulations	Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
Historique des statuts LME	Ajouté pour la première fois en 2007 (TRS 946) Modifié en 2021 (TRS 1035)
Sexe	Tous
Âge	Adolescents et adultes
Équivalence thérapeutique	efavirenz + lamivudine + tenofovir (Codes ATC: J05AR11)
Renseignements sur le brevet	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org Lire la suite sur les brevets.
Wikipédia	Efavirenz + emtricitabine + tenofovir
DrugBank	Efavirenz , Emtricitabine , Tenofovir disoproxil

Résumé des preuves et recommandation du comité d'experts

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified as a therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.

